ECSP12012138A - Anticuerpo monoclonico anti-cd44 que liga el carcinoma escamocelular de cabeza y cuello - Google Patents
Anticuerpo monoclonico anti-cd44 que liga el carcinoma escamocelular de cabeza y cuelloInfo
- Publication number
- ECSP12012138A ECSP12012138A ECSP12012138A ECSP12012138A EC SP12012138 A ECSP12012138 A EC SP12012138A EC SP12012138 A ECSP12012138 A EC SP12012138A EC SP12012138 A ECSP12012138 A EC SP12012138A
- Authority
- EC
- Ecuador
- Prior art keywords
- cdmab
- antibodies
- neck
- head
- binding fragments
- Prior art date
Links
- 201000009030 Carcinoma Diseases 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 230000007402 cytotoxic response Effects 0.000 abstract 1
- 230000003013 cytotoxicity Effects 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000013210 hematogenous Diseases 0.000 abstract 1
- 210000004408 hybridoma Anatomy 0.000 abstract 1
- 238000003018 immunoassay Methods 0.000 abstract 1
- 229940079322 interferon Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002285 radioactive effect Effects 0.000 abstract 1
- 206010041823 squamous cell carcinoma Diseases 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
- 108700012359 toxins Proteins 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Esta invención se relaciona con el estadiaje, diagnóstico y tratamiento contra enfermedades cancerosas (tanto tumores primarios como metástasis tumorales), particularmente a la mediación de citotoxicidad de células tumorales; y más particularmente al uso de anticuerpos monoclónicos, fragmentos de unión al antígeno de lo mismo, y/o anticuerpos modificadores de enfermedad cancerosa (CDMAB), opcionalmente combinados con uno o más CDMAB, con agentes quimioterapéuticos y conjugados de lo mismo, como unos medios para iniciar una respuesta citotóxica a carcinomas escamocelulares de cabeza y cuello en humano. La invención adicionalmente se relaciona con inmunoensayos que utilizan anticuerpos monoclónicos, fragmentos de unión al antígeno de lo mismo, y/o CDMAB de la invención actual. Los anticuerpos modificadores de enfermedad cancerosa pueden conjugarse a toxinas, enzimas, compuestos radiactivos, citocinas, interferón, porciones con especificidad de objetivo o indicadoras y células hematógenas. En aspectos particulares, el CDMAB usado en los métodos de la invención es un anticuerpo anti-CD44, que puede ser el anticuerpo producido por el hibridoma depositado con el ATCC que tiene el número de acceso PTA-4621 y/o una versión quimérica o humanizada del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30144910P | 2010-02-04 | 2010-02-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP12012138A true ECSP12012138A (es) | 2012-09-28 |
Family
ID=43858306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP12012138 ECSP12012138A (es) | 2010-02-04 | 2012-09-04 | Anticuerpo monoclonico anti-cd44 que liga el carcinoma escamocelular de cabeza y cuello |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US20130224108A1 (es) |
| EP (1) | EP2531527B1 (es) |
| JP (2) | JP5763105B2 (es) |
| KR (1) | KR20130042466A (es) |
| CN (1) | CN102741292B (es) |
| AU (1) | AU2011212485B2 (es) |
| BR (1) | BR112012019475A8 (es) |
| CA (1) | CA2786337A1 (es) |
| CL (1) | CL2012001980A1 (es) |
| CR (1) | CR20120429A (es) |
| DK (1) | DK2531527T3 (es) |
| EC (1) | ECSP12012138A (es) |
| ES (1) | ES2460945T3 (es) |
| HR (1) | HRP20140513T1 (es) |
| IL (1) | IL220092A (es) |
| MA (1) | MA34010B1 (es) |
| MX (1) | MX2012008699A (es) |
| MY (1) | MY157532A (es) |
| NZ (1) | NZ600079A (es) |
| PE (1) | PE20130380A1 (es) |
| PL (1) | PL2531527T3 (es) |
| PT (1) | PT2531527E (es) |
| RS (1) | RS53327B (es) |
| RU (1) | RU2599447C2 (es) |
| SG (2) | SG10201505118PA (es) |
| SI (1) | SI2531527T1 (es) |
| TW (1) | TW201130512A (es) |
| WO (1) | WO2011095498A1 (es) |
| ZA (1) | ZA201205649B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012019475A8 (pt) * | 2010-02-04 | 2017-12-26 | Hoffmann La Roche | uso de um anticorpo monoclonal anti-cd44, anticorpo monoclonal anti-cd44, anticorpo anti-cd44 humanizado e kit para a detecção da presença de hnscc em uma amostra |
| KR20140090997A (ko) * | 2011-10-26 | 2014-07-18 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | B-세포 만성 림프구성 백혈병 및 다른 혈액학적 악성종양의 치료를 위한 cd44 단일클론 항체 |
| US20140335084A1 (en) * | 2011-12-06 | 2014-11-13 | Hoffmann-La Roche Inc. | Antibody formulation |
| US20150044232A1 (en) * | 2013-06-12 | 2015-02-12 | Hoffmann-La Roche Inc. | Markers for the responsiveness to anti-cd44 antibodies |
| CA2919975C (en) * | 2013-07-31 | 2022-11-01 | University Of Miami | Compositions and methods for identifying a risk of cancer in a subject |
| WO2015076425A1 (ja) * | 2013-11-25 | 2015-05-28 | リンク・ジェノミクス株式会社 | 新規モノクローナル抗体 |
| KR102215384B1 (ko) * | 2014-06-11 | 2021-02-15 | (재) 스크립스코리아항체연구원 | CD44v3 도메인 3 및 도메인 6 특이적 단일클론 항체 및 그 용도 |
| TWI535452B (zh) | 2015-01-23 | 2016-06-01 | 長庚醫療財團法人 | 使用抗－ｃｄ４４中和抗體來治療和／或預防心房顫動 |
| JP2023526529A (ja) | 2020-05-19 | 2023-06-21 | アンスティテュ・クリー | サイトカイン放出症候群の診断及び処置の方法 |
| EP4301782A1 (en) * | 2021-03-05 | 2024-01-10 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DE19545472A1 (de) * | 1995-12-06 | 1997-06-12 | Boehringer Ingelheim Int | Verfahren zur Diagnose und Therapie von Plattenepithelkarzinomen |
| UY24389A1 (es) * | 1995-12-06 | 2001-10-25 | Karlsruhe Forschzent | Composición farmacéutica para el tratamiento de carcinoma de epitelio plano |
| US8048416B2 (en) * | 1999-10-08 | 2011-11-01 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US20090004103A1 (en) * | 1999-10-08 | 2009-01-01 | Young David S F | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US6180357B1 (en) | 1999-10-08 | 2001-01-30 | Arius Research, Inc. | Individualized patient-specific anti-cancer antibodies |
| US7252821B2 (en) | 1999-10-08 | 2007-08-07 | Arius Research Inc. | Cancerous disease modifying antibodies |
| US8071072B2 (en) * | 1999-10-08 | 2011-12-06 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US20050100542A1 (en) | 1999-10-08 | 2005-05-12 | Young David S. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US20030103985A1 (en) * | 2001-05-18 | 2003-06-05 | Boehringer Ingelheim International Gmbh | Cytotoxic CD44 antibody immunoconjugates |
| CA2443437A1 (en) | 2001-05-18 | 2002-11-28 | Boehringer Ingelheim International Gmbh | Antibodies specific for cd44v6 |
| AU2003272511A1 (en) * | 2002-09-13 | 2004-04-30 | Dyax Corporation | Cd44-binding ligands |
| EP1532984A1 (en) * | 2003-11-19 | 2005-05-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti CD44 antibodies for eradicating stem cells in acute myeloid leukemia |
| BR112012019475A8 (pt) * | 2010-02-04 | 2017-12-26 | Hoffmann La Roche | uso de um anticorpo monoclonal anti-cd44, anticorpo monoclonal anti-cd44, anticorpo anti-cd44 humanizado e kit para a detecção da presença de hnscc em uma amostra |
-
2011
- 2011-02-02 BR BR112012019475A patent/BR112012019475A8/pt not_active IP Right Cessation
- 2011-02-02 CN CN201180008111.1A patent/CN102741292B/zh not_active Expired - Fee Related
- 2011-02-02 PL PL11703182T patent/PL2531527T3/pl unknown
- 2011-02-02 SI SI201130171T patent/SI2531527T1/sl unknown
- 2011-02-02 ES ES11703182.3T patent/ES2460945T3/es active Active
- 2011-02-02 MX MX2012008699A patent/MX2012008699A/es active IP Right Grant
- 2011-02-02 MA MA35156A patent/MA34010B1/fr unknown
- 2011-02-02 SG SG10201505118PA patent/SG10201505118PA/en unknown
- 2011-02-02 AU AU2011212485A patent/AU2011212485B2/en not_active Ceased
- 2011-02-02 WO PCT/EP2011/051436 patent/WO2011095498A1/en active Application Filing
- 2011-02-02 PE PE2012001162A patent/PE20130380A1/es not_active Application Discontinuation
- 2011-02-02 RU RU2012137380/10A patent/RU2599447C2/ru not_active IP Right Cessation
- 2011-02-02 MY MYPI2012003179A patent/MY157532A/en unknown
- 2011-02-02 DK DK11703182.3T patent/DK2531527T3/da active
- 2011-02-02 KR KR1020127022586A patent/KR20130042466A/ko not_active Application Discontinuation
- 2011-02-02 NZ NZ600079A patent/NZ600079A/xx not_active IP Right Cessation
- 2011-02-02 PT PT117031823T patent/PT2531527E/pt unknown
- 2011-02-02 CA CA2786337A patent/CA2786337A1/en not_active Abandoned
- 2011-02-02 EP EP11703182.3A patent/EP2531527B1/en not_active Not-in-force
- 2011-02-02 SG SG2012054847A patent/SG182704A1/en unknown
- 2011-02-02 JP JP2012551602A patent/JP5763105B2/ja not_active Expired - Fee Related
- 2011-02-02 RS RS20140251A patent/RS53327B/en unknown
- 2011-02-04 US US13/021,442 patent/US20130224108A1/en not_active Abandoned
- 2011-02-08 TW TW100104223A patent/TW201130512A/zh unknown
-
2012
- 2012-05-31 IL IL220092A patent/IL220092A/en not_active IP Right Cessation
- 2012-07-17 CL CL2012001980A patent/CL2012001980A1/es unknown
- 2012-07-26 ZA ZA2012/05649A patent/ZA201205649B/en unknown
- 2012-08-17 CR CR20120429A patent/CR20120429A/es unknown
- 2012-09-04 EC ECSP12012138 patent/ECSP12012138A/es unknown
-
2014
- 2014-06-03 HR HRP20140513AT patent/HRP20140513T1/hr unknown
-
2015
- 2015-02-27 JP JP2015038519A patent/JP6037149B2/ja not_active Expired - Fee Related
- 2015-09-03 US US14/845,134 patent/US20150374848A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP12012138A (es) | Anticuerpo monoclonico anti-cd44 que liga el carcinoma escamocelular de cabeza y cuello | |
| PH12020551160A1 (en) | Chimeric antigen receptors targeting cd70 | |
| CO6140062A2 (es) | Anticuerpos anti-trop-2 humanizados y quiméricos que median citotoxicidad de celulas cancerosas | |
| CL2020003046A1 (es) | Construcciones de anticuerpo biespecificos que se unen a dll3 y cd3 ( divisional de la solicitud 267-2018) | |
| PE20191208A1 (es) | Anticuerpos anti-cd73 y usos de los mismos | |
| CL2017001580A1 (es) | Anticuerpo o fragmento de anticuerpo contra cd38 anticuerpo humanizado, conjugado del anticuerpo con un compuesto citotoxico composición farmacéutica con dichos anticuerpos uso de los anticuerpos para tratar cáncer o enfermedad autoinmune método para diagnosticar cáncer polinucleotido vector y célula huésped. | |
| JOP20210289A1 (ar) | مقترنات عقار - جسم مضاد مثبط لـmcl-1 وطرق لاستخدامها | |
| RU2016150377A (ru) | Сайт-специфичная конъюгация линкерных лекарственных препаратов с антителами и получаемые в результате adc | |
| ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
| CU20130130A7 (es) | Anticuerpos tipo receptor de células t específicos para un péptido wt1 presentado por hla-a2 | |
| PE20091024A1 (es) | Anticuerpos monoclonales que se unen a anexelekto y sus usos | |
| MX2021015888A (es) | Fusión de un anticuerpo que se une a cea y 4-1bbl. | |
| CO6241160A2 (es) | Anticuerpos anti-cd44 quiméricos y humanizados que median la citotoxicidad de celulas de cancer | |
| RU2014103784A (ru) | Антитело, блокирующее agr2, и его применение | |
| WO2019112347A3 (ko) | 악성 b 세포를 특이적으로 인지하는 항체 또는 그의 항원 결합 단편, 이를 포함하는 키메라 항원 수용체 및 이의 용도 | |
| RU2016143552A (ru) | Гуманизированные антитела к антигену Томсена-Фриденрайха | |
| ZA202008095B (en) | Humanized antibodies against psma | |
| AR077972A1 (es) | Anticuerpos contra cdcp1 destinados al tratamiento del cancer | |
| MX2022005816A (es) | Terapia de tumores solidos cd70+ utilizando linfocitos t genomodificados dirigidos a cd70. | |
| AR081321A1 (es) | N-cadherina: un blanco para el diagnostico y la terapia del cancer | |
| MX2022005949A (es) | Anticuerpos anti-ror-2 y metodos de uso. | |
| EP4032550A3 (en) | Humanized anti-cd19 antibody and use thereof with chimeric antigen receptor | |
| PE20142277A1 (es) | Anticuerpos recombinantes con especificidad dual por gangliosidos y su uso | |
| AR070279A1 (es) | Anticuerpos modificadores de enfermedades cancerosas (cdma) | |
| AR108451A1 (es) | Anticuerpos anti-tenascina modificados y métodos de utilización |